HLA-DRB1 alleles in juvenile-onset systemic lupus erythematosus: renal histologic class correlations

B.L. Liphaus¹, M.H.B. Kiss² and A.C. Goldberg³

Abstract

Human leukocyte antigens (HLA) DRB1*03 and DRB1*02 have been associated with systemic lupus erythematosus (SLE) in Caucasians and black populations. It has been observed that certain HLA alleles show stronger associations with SLE autoantibodies and clinical subsets, although they have rarely been associated with lupus renal histologic class. In the present study, HLA-DRB1 allele correlations with clinical features, autoantibodies and renal histologic class were analyzed in a cohort of racially mixed Brazilian patients with juvenile-onset SLE. HLA-DRB1 typing was carried out by polymerase chain reaction amplification with sequence-specific primers using genomic DNA from 55 children and adolescents fulfilling at least four of the American College of Rheumatology criteria for SLE. Significance was determined by the chi-square test applied to 2 x 2 tables. The HLA-DRB1*15 allele was most frequent in patients with renal, musculoskeletal, cutaneous, hematologic, cardiac, and neuropsychiatric involvement, as well as in patients positive for anti-dsDNA, anti-Sm, anti-U1-RNP, and anti-SSA/Ro antibodies, although an association between HLA alleles and SLE clinical features and autoantibodies could not be observed. The HLA-DRB1*17, HLA-DRB1*10, HLA-DRB1*15, and HLA-DRB1*07 alleles were significantly higher in patients with renal histologic class I, class IIA, class IIB, and class V, respectively. The present results suggest that the contribution of HLA-DRB1 alleles to juvenile-onset SLE could not be related to clinical or serological subsets of the disease, but it may be related to renal histologic classes, especially class I, class II A, class II B, and class V. The latter correlations have not been observed in literature.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multisystem organ involvement and autoantibodies production (1). Genetic factors are likely to be important both in determining the overall susceptibility to SLE and influencing the remarkable clinical heterogeneity of disease presentation and autoantibody production observed in affected subjects (2). Human leukocyte antigen (HLA) DRB1*02 and the allelic variant DRB1*15 have been associated with SLE in blacks and Asians and HLA-DRB1*03 has been associated with lupus in Caucasians, but clear associations...
with HLA and SLE could not be demonstrated in racially mixed populations (2-5). It is recognized that certain HLA alleles show stronger association with autoantibody repertoires and clinical subsets than with SLE itself. Some studies have observed an association with HLA alleles and cutaneous or cardiac involvement (6). In addition, most studies showed an association between HLA-DRB1*02 and DRB1*15 and lupus nephritis, although HLA alleles have rarely been associated with SLE renal histologic class (3,4,6,7). The association with HLA and SLE in children appears to be similar to that observed in adults, but clinical involvement, autoantibodies and renal histologic class frequencies are quite different in these two groups (8).

We conducted this study to determine HLA-DRB1 allele associations with SLE clinical subsets, autoantibodies and renal histologic class in a cohort of Brazilian children and adolescents.

Patients and Methods

Patients

We studied 55 consecutive Brazilian children and adolescents with SLE attending the Rheumatology Unit, Children’s Institute, Faculty of Medicine, University of São Paulo. All patients met the American College of Rheumatology classification criteria for SLE (9). The study was approved by the local Ethics Committee and all patients or persons responsible gave written informed consent to participate. Patient mean age at disease onset was 10.4 years (range, 1-17 years), mean follow-up period was 3.5 years (range, 1-13 years) and 46 patients (84%) were females (female: male ratio of 5.1:1). Clinical and serologic characteristics were recorded on a specific protocol form. The definitions of the clinical features were based on the American College of Rheumatology criteria (9). Forty-three patients underwent a renal biopsy and renal histologic class was established according to the World Health Organization (WHO) classification of lupus nephritis (1,10).

Laboratory investigations

Serologic tests were performed in the same laboratory for all patients. Antinuclear antibodies were determined by indirect immunofluorescence using rat liver sections or human cell line HEp-2 as substrate (sera diluted 1/40). Anti-dsDNA antibodies were determined by indirect immunofluorescence with *Crithidia luciliae* as substrate (sera diluted 1/10). Precipitating antibodies to extractable nuclear antigens, including SSA/Ro, SSB/La, U1-RNP and Sm were detected by enzyme-linked immunosorbent assay. The anti-ribosomal P antibody was also detected by enzyme-linked immunosorbent assay. A total of 14 HLA-DRB1 alleles (*01, *15, *16, *17, *18, *04, *11, *12, *13, *14, *07, *08, *09, *10) were identified by polymerase chain reaction amplification with sequence-specific primers. The method was based on the procedure developed by Olerup and Zetterquist (11). Genomic DNA was extracted from peripheral blood mononuclear cells by the DTAB/CTAB method (12). Briefly, the buffy coat from 5 mL blood was vigorously mixed with 12% DTAB solution (12% DTAB, 2.25 M NaCl, 150 mM Tris, pH 8.6, 75 mM EDTA) and incubated for 5 min at 68°C. After the addition of 2 volumes of chloroform, samples were vigorously mixed and centrifuged for 2 min at 10,000 g for separation into three phases. The upper phase was transferred to a fresh tube containing 2 volumes of 0.5% CTAB (0.5% CTAB, 0.04 M NaCl) and DNA was precipitated and further washed with 99.5% ethanol. PCR was carried out for 35 cycles under the following conditions: 200 ng DNA, 10 mM Tris-HCl, pH 8.4, 50 mM KCl, 2 mM MgCl2, 0.001% gelatin, 0.2 mM dNTP, 20 pmol of each primer, 2 U Taq DNA poly-
merase, and H2O up to 55 µL were denatured for 1 min at 94ºC, annealed for 1 min at 55ºC, with an extension at 72ºC for 1 min. The PCR products were identified by 1.2% agarose gel electrophoresis.

**Statistical analysis**

To compare the HLA allele frequencies of SLE patients with and without the various clinical characteristics, autoantibodies and renal histologic class, the conventional chi-square test with Yates’ correction for continuity or, when appropriate, the Fisher exact test (two-tailed) were used. The odds ratio was calculated with 2 x 2 contingency tables. The 95% confidence intervals were obtained using Cornfield’s approximation. The P value was corrected for the number of alleles tested. The level of significance was set at 95% (13).

**Results**

The following clinical manifestations and autoantibodies were detected in this group of 55 children and adolescents with SLE: cutaneous involvement (N = 53, 96%), musculoskeletal involvement (N = 42, 76%), lung involvement (N = 13, 24%), cardiac involvement (N = 23, 42%), and neuropsychiatric involvement (N = 25, 45%); renal (N = 45, 82%) and hematologic (N = 47, 85%) abnormalities; 55 (100%) had anti-nuclear antibodies, 38 (69%) anti-dsDNA, 17 (31%) anti-Sm, 20 (36%) anti-U1-RNP, 19 (34%) anti-SSA/Ro, and 6 (11%) anti-SSB/La antibodies. Eleven patients were tested for the anti-ribosomal P antibody, which was positive in 3 (27%).

HLA-DRB1*15, an allelic variant of DRB1*02, was more frequently detected in SLE patients with renal, musculoskeletal, cutaneous, hematologic, cardiac, and neuropsychiatric features compared with SLE patients without these clinical features, although a statistical significant association between HLA alleles and SLE clinical involvement could not be demonstrated (Table 1). As expected, the HLA-DRB1*15 allele was more frequent in patients with positive anti-dsDNA, anti-Sm, anti-U1-RNP, and anti-SSA/Ro antibodies; HLA-DRB1*04 and HLA-DRB1*07 were most frequent in patients with positive anti-SSB/La antibody; the HLA-DRB1*13 allele was more frequent in patients with positive anti-ribosomal P antibody, although the differences were not statistically significant (Table 2).

The patterns of glomerular damage seen in 43 renal biopsies according to the WHO classification of lupus nephritis were: minimal mesangial glomerulonephritis in 6 patients (14%) (class I), mesangial glomerulonephritis A in 6 (14%) (class IIA), mesangial

<table>
<thead>
<tr>
<th>Clinical manifestations</th>
<th>HLA + (%)</th>
<th>- (%)</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nephritis</td>
<td>DRB1*15</td>
<td>31.1</td>
<td>40.0</td>
<td>0.68 0.14-3.46</td>
</tr>
<tr>
<td>Musculoskeletal involvement</td>
<td>DRB1*15</td>
<td>28.5</td>
<td>54.5</td>
<td>0.47 0.11-2.0</td>
</tr>
<tr>
<td>Cutaneous involvement</td>
<td>DRB1*15</td>
<td>33.9</td>
<td>0.0</td>
<td>- -</td>
</tr>
<tr>
<td>Hematologic abnormalities</td>
<td>DRB1*15</td>
<td>31.9</td>
<td>37.5</td>
<td>0.78 0.13-4.84</td>
</tr>
<tr>
<td>Lung involvement</td>
<td>DRB1*04</td>
<td>38.4</td>
<td>14.3</td>
<td>3.75 0.75-19.3</td>
</tr>
<tr>
<td>Cardiac involvement</td>
<td>DRB1*15</td>
<td>30.4</td>
<td>34.4</td>
<td>0.84 0.23-3.04</td>
</tr>
<tr>
<td>Cardiac involvement</td>
<td>DRB1*07</td>
<td>30.4</td>
<td>21.8</td>
<td>1.56 0.39-6.26</td>
</tr>
<tr>
<td>Neuropsychiatric involvement</td>
<td>DRB1*15</td>
<td>32.0</td>
<td>33.3</td>
<td>0.94 0.26-3.37</td>
</tr>
<tr>
<td>Neuropsychiatric involvement</td>
<td>DRB1*13</td>
<td>32.0</td>
<td>56.7</td>
<td>2.35 0.56-10.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Autoantibodies</th>
<th>HLA + (%)</th>
<th>- (%)</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-dsDNA</td>
<td>DRB1*15</td>
<td>31.5</td>
<td>22.2</td>
<td>0.85 0.22-3.34</td>
</tr>
<tr>
<td>Anti-Sm</td>
<td>DRB1*15</td>
<td>47.1</td>
<td>26.3</td>
<td>2.49 0.65-9.77</td>
</tr>
<tr>
<td>Anti-U1-RNP</td>
<td>DRB1*15</td>
<td>45.0</td>
<td>25.7</td>
<td>2.36 0.64-8.91</td>
</tr>
<tr>
<td>Anti-SSA/Ro</td>
<td>DRB1*15</td>
<td>36.8</td>
<td>30.5</td>
<td>1.33 0.35-4.99</td>
</tr>
<tr>
<td>Anti-SSB/La</td>
<td>DRB1*04</td>
<td>33.3</td>
<td>18.4</td>
<td>2.22 0.24-18.1</td>
</tr>
<tr>
<td>Anti-SSB/La</td>
<td>DRB1*07</td>
<td>33.3</td>
<td>24.5</td>
<td>1.54 0.17-11.9</td>
</tr>
<tr>
<td>Anti-ribosomal P antibody</td>
<td>DRB1*13</td>
<td>66.6</td>
<td>21.2</td>
<td>8.40 0.51-262.3</td>
</tr>
</tbody>
</table>

HLA = human leukocyte antigen; OR = odds ratio; 95%CI = 95% confidence interval. All P values were ≥0.10.
glomerulonephritis B in 8 (19%) (class IIB), focal proliferative glomerulonephritis in 4 (9%) (class III), diffuse proliferative glomerulonephritis in 4 (9%) (class IV), and membranous glomerulonephritis in 15 (35%) (class V).

HLA-DRB1*17, a subtype of DRB1*03, was positively associated with renal histologic class I (P = 0.034) compared with SLE patients belonging to other renal histologic classes. Similarly, HLA-DRB1*10 was associated with class IIA (P = 0.03), HLA-DRB1*15 with class IIB (P = 0.011) and HLA-DRB1*07 with class V (P = 0.012), although the differences were not statistically significant after correction for the number of comparisons (Table 3).

**Discussion**

Multiple loci can contribute to SLE susceptibility and disease pathogenesis is expressed as a complex genetic interaction that is undoubtedly influenced by environmental factors (2). Genetic studies of SLE are difficult because the disease is heterogeneous and can be divided into several clinical and immunologic subsets, each with its own genetic background (2). Furthermore, genes predisposing to SLE may vary according to patient ethnic group (2,3).

Several studies, including association and family investigations, have confirmed the linkage of the SLE and MHC region in humans. The HLA-DRB1*03 allele has been associated with SLE in Caucasian populations while the HLA-DRB1*02 allele and the HLA-DRB1*15 and HLA-DRB1*16 subtypes have been associated with SLE in black and Asian ethnic groups (2-4,6,14-21). The association of HLA-DRB1*07 and HLA-DRB1*13 with lupus was observed in a few studies, such as that by Wilson et al. (22) on African Americans and that by Cowland et al. (23) in Denmark. Barron et al. (24) showed similar associations in children with SLE: HLA-DR3 (DRB1*0301) in Caucasians and HLA-DR2 (DRB1*1503/DRB1*1501), DRB5*0101, DQA1*0102, and DQB1*0602 in blacks. In Taiwanese patients with juvenile-onset SLE there was an association with HLA-DRB1*1602 (21).

Silva and Donadi (25), studying 93 Brazilian SLE patients aged 13 to 66 years, observed a higher frequency of HLA-DRB1*03, a result that differs from that observed in our previous study on 55 children and adolescents with SLE in which HLA-DRB1*15 was the most frequent allele (5), and from that reported by Fernandes et al. (26) in a study on 56 adult patients with SLE in which HLA-DRB1*02 was the most frequent allele.

It has been suggested that certain MHC haplotypes show stronger association with SLE clinical manifestations and autoantibodies than with the disease itself (3,4). In infants, SLE has been reported to be clinically and serologically different, with a higher frequency of renal involvement and mortality compared to adults (1.8). These differences raise some questions regarding the possibility that childhood SLE could be a disease with its own genetic background.

We observed that the HLA-DRB1*15 allele was most frequent in patients with cutaneous, cardiac, neuropsychiatric, renal,

---

**Table 3. Relative HLA phenotype frequency according to renal histologic class in 55 children and adolescents with systemic lupus erythematosus.**

<table>
<thead>
<tr>
<th>Renal histologic class</th>
<th>HLA</th>
<th>+ (%)</th>
<th>- (%)</th>
<th>Pc value</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>DRB1*17</td>
<td>50.0%</td>
<td>10.2%</td>
<td>0.47</td>
<td>8.80</td>
<td>1.03-82.4</td>
</tr>
<tr>
<td>Class IIA</td>
<td>DRB1*01</td>
<td>33.3%</td>
<td>23.0%</td>
<td>-</td>
<td>2.56</td>
<td>1.27-10.14</td>
</tr>
<tr>
<td>Class IIB</td>
<td>DRB1*11</td>
<td>33.3%</td>
<td>10.2%</td>
<td>-</td>
<td>4.40</td>
<td>1.42-12.56</td>
</tr>
<tr>
<td>Class III</td>
<td>DRB1*07</td>
<td>33.3%</td>
<td>24.5%</td>
<td>-</td>
<td>1.54</td>
<td>0.17-11.94</td>
</tr>
<tr>
<td>Class IV</td>
<td>DRB1*10</td>
<td>33.3%</td>
<td>21.1%</td>
<td>0.42</td>
<td>24.0</td>
<td>1.25-878.2</td>
</tr>
<tr>
<td>Class V</td>
<td>DRB1*15</td>
<td>75.0%</td>
<td>25.5%</td>
<td>0.15</td>
<td>8.75</td>
<td>1.30-73.7</td>
</tr>
<tr>
<td>Class IIA</td>
<td>DRB1*15</td>
<td>50.0%</td>
<td>31.5%</td>
<td>-</td>
<td>2.19</td>
<td>0.20-24.6</td>
</tr>
<tr>
<td>Class IIB</td>
<td>DRB1*11</td>
<td>50.0%</td>
<td>23.5%</td>
<td>-</td>
<td>3.25</td>
<td>0.28-37.5</td>
</tr>
<tr>
<td>Class III</td>
<td>DRB1*17</td>
<td>50.0%</td>
<td>11.7%</td>
<td>-</td>
<td>7.50</td>
<td>0.60-98.9</td>
</tr>
<tr>
<td>Class IV</td>
<td>DRB1*08</td>
<td>50.0%</td>
<td>13.7%</td>
<td>-</td>
<td>6.29</td>
<td>0.51-79.6</td>
</tr>
<tr>
<td>Class V</td>
<td>DRB1*07</td>
<td>53.0%</td>
<td>15.0%</td>
<td>0.16</td>
<td>6.48</td>
<td>1.43-31.0</td>
</tr>
</tbody>
</table>

HLA = human leukocyte antigen; OR = odds ratio; 95%CI = 95% confidence interval; Pc value = P value corrected for 14 comparisons.
and hematologic involvement, although an association could not be demonstrated. Doherty et al. (6) described an association with HLA-DR15 and SLE skin involvement in Chinese patients and Reivelle et al. (27) demonstrated an association with HLA-DR53 and HLA-DQA1 and malar erythema photosensitivity. Doherty et al. (6) also reported an association with the HLA-DR7 and HLA-DR9 alleles and cardiac involvement in Chinese patients. None of our patients with cardiac involvement presented the HLA-DRB1*09 allele. In the Brazilian study of Silva and Donadi (25), HLA-DR3, HLA-DR9 and HLA-DQ2 were the most frequent alleles in SLE patients with neuropsychiatric involvement, a result that differs from that observed in the present study. Fronek et al. (7) and Doherty et al. (6) described an association with HLA-DR2 and SLE nephritis in Americans. Lupus nephritis has also been associated with the HLA-DR3, HLA-DR15 and HLA-DR16 alleles in different ethnic groups (6,7,28). There is no description in the literature of an association between HLA alleles and SLE nephritis. Galeazzi et al. (28) described an association between HLA-DR and SLE renal histologic class. Nevertheless, HLA alleles have rarely been associated with SLE renal histologic class. The renal histologic class frequencies observed in the present study were similar to those reported in the literature (1,8). Interestingly, 3 of 6 patients belonging to WHO renal histologic class I showed HLA-DRB1*17, an allelic variant of DRB1*03. HLA-DRB1*03 has been associated with SLE patients with disease onset after 35 years of age, who have less frequent and less severe renal involvement (2), possibly suggesting a protective effect of the HLA-DRB1*03 allele for lupus nephritis. On the other hand, Shankarkumar et al. (35), studying 53 patients with severe SLE who had one or more organ affected, such as kidney, brain, heart, and lungs, observed that the HLA-DRB1*03 allele was significantly increased in this group. Only 3 of the 55 children and adolescents with SLE presented HLA-DRB1*10 and 2 of them belonged to renal histologic class IIA. Eight patients belonged to class IIB and 6 of them presented the HLA-DRB1*15 allele, although our study could not demonstrate an association between HLA-DRB1*15 and lupus nephritis per se. Fifteen patients had membranous glomerulonephritis (class V) and 8 presented HLA-DRB1*07. These findings are different from those observed by Marchini et al. (36), who showed an association between HLA-DRB1*15 and severe form of lupus glomerulonephritis class III.
and class IV. Interestingly, Endreffy et al. (37) observed that the DRB1*1501 allele was less frequent in patients with lupus nephritis. In contrast, HLA-DRB1*03 and DRB1*07 alleles were more frequent in patients with lupus nephritis. In addition, HLA-DR expression was significantly increased in kidney arteries and arterioles of SLE patients compared to controls, although it did not correlate with WHO renal histologic class (38). The extended HLA-A1,B8,DR3 haplotype has been associated with idiopathic membranoproliferative glomerulonephritis and with SLE (39). The individual HLA-DR3, HLA-DR15 and HLA-DR7 components have been associated with membranous idiopathic nephropathy, membranoproliferative glomerulonephritis and idiopathic nephrotic syndrome, respectively (39). Recently, a Brazilian study observed an association between DD genotype of the angiotensin-converting enzyme and SLE renal histologic classes III and IV (40).

The present results suggest that the contribution of MHC genes to SLE cannot be only related to the clinical and serological subsets of the disease but also to its renal histologic class.

References

22. Wilson WA, Scoppettii E, Michalski JP. Association of HLA-DR7 with both antibody to SSA(Ro) and disease susceptibility in blacks with systemic lupus erythematosus. J Rheumatol 1984; 11: 653-657.


33. Teh LS, Doherty DG, Williams BD. HLA-DRB genes and antibo-


35. Shankarkumar U, Ghosh K, Badakere SS, Mohanty D. HLA-
DRB1*03 and DQB1*0302 associations in a subset of patients severely affected with systemic lupus erythematosus from western India. *Ann Rheum Dis* 2003; 62: 92-93.


